Skip to content
Lumefantrine
Coartem (lumefantrine) is a small molecule pharmaceutical. Lumefantrine was first approved as Coartem on 2009-04-07. It is used to treat falciparum malaria and malaria in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
Trade Name
FDA
EMA
Combinations
Coartem
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Artemether
+
Lumefantrine
Tradename
Company
Number
Date
Products
COARTEMNovartisN-022268 RX2009-04-07
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
coartemNew Drug Application2020-06-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
falciparum malariaEFO_0007444D016778B50
malariaEFO_0001068D008288B54
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01B: Antimalarials
— P01BF: Artemisinin and derivatives, combinations
— P01BF01: Artemether and lumefantrine
HCPCS
No data
Clinical
Clinical Trials
167 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B54129244521106
Falciparum malariaD016778EFO_0007444B502101620647
Vivax malariaD016780EFO_0007445B51112419
Hiv infectionsD015658EFO_0000764B202—16—9
HivD006678O98.72——1—3
AnemiaD000740EFO_0004272D64.9———2—2
Drug interactionsD004347———1—1
TuberculosisD014376EFO_0000774A15-A19———1—1
SchistosomiasisD012552EFO_1001475B65———1—1
HelminthiasisD006373EFO_1001342B65-B83———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.1——1——1
FeverD005334HP_0001945R50.9——1——1
Asymptomatic diseasesD058070—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—31———3
PharmacokineticsD01059921———2
Schistosomiasis haematobiaD012553EFO_0007530B65.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parasitic diseasesD010272EFO_0001067B881————1
ParasitemiaD0185121————1
Protozoan infectionsD011528B50-B641————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PneumoniaD011014EFO_0003106J18————22
MalnutritionD044342EFO_0008572E40-E46————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLUMEFANTRINE
INNlumefantrine
Description
Lumefantrine is a member of the class of fluorenes that is 9-(p-chlorobenzylidene)-9H-fluorene which is substitutec by chlorine at positions 2 and 7, and by a 2-(dibutylamino)-1-hydroxyethyl group at position 4. An antimalarial drug used in combination with artemether for the treatment of multi-drug resistant strains of falciparum malaria. It has a role as an antimalarial. It is a tertiary amine, a member of monochlorobenzenes, a secondary alcohol and a member of fluorenes.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1
Identifiers
PDB—
CAS-ID82186-77-4
RxCUI—
ChEMBL IDCHEMBL38827
ChEBI ID156095
PubChem CID6437380
DrugBankDB06708
UNII IDF38R0JR742 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,057 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
65,198 adverse events reported
View more details